We wish to inform you that the United States Food and Drug Administration ("US FDA") has inspected our Unit 1 manufacturing facility at Bonthapally, Hyderabad from 18th to 22nd March 2024. The inspection at Unit 1 by the US FDA has been successfully completed, with no observations under Form 483.